JP2012532200A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532200A5
JP2012532200A5 JP2012519672A JP2012519672A JP2012532200A5 JP 2012532200 A5 JP2012532200 A5 JP 2012532200A5 JP 2012519672 A JP2012519672 A JP 2012519672A JP 2012519672 A JP2012519672 A JP 2012519672A JP 2012532200 A5 JP2012532200 A5 JP 2012532200A5
Authority
JP
Japan
Prior art keywords
antigen
vesicle
lipid
molten
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519672A
Other languages
English (en)
Japanese (ja)
Other versions
JP5854559B2 (ja
JP2012532200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/041078 external-priority patent/WO2011005769A1/en
Publication of JP2012532200A publication Critical patent/JP2012532200A/ja
Publication of JP2012532200A5 publication Critical patent/JP2012532200A5/ja
Application granted granted Critical
Publication of JP5854559B2 publication Critical patent/JP5854559B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519672A 2009-07-06 2010-07-06 小胞を調製する方法及びこれから製造される製剤 Expired - Fee Related JP5854559B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22319609P 2009-07-06 2009-07-06
US61/223,196 2009-07-06
US25691209P 2009-10-30 2009-10-30
US61/256,912 2009-10-30
PCT/US2010/041078 WO2011005769A1 (en) 2009-07-06 2010-07-06 Methods for preparing vesicles and formulations produced therefrom

Publications (3)

Publication Number Publication Date
JP2012532200A JP2012532200A (ja) 2012-12-13
JP2012532200A5 true JP2012532200A5 (enExample) 2013-08-22
JP5854559B2 JP5854559B2 (ja) 2016-02-09

Family

ID=43429505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519672A Expired - Fee Related JP5854559B2 (ja) 2009-07-06 2010-07-06 小胞を調製する方法及びこれから製造される製剤

Country Status (11)

Country Link
US (1) US9849173B2 (enExample)
EP (1) EP2451950B9 (enExample)
JP (1) JP5854559B2 (enExample)
CN (2) CN107029229B (enExample)
AU (1) AU2010270722B2 (enExample)
BR (1) BR112012000826B1 (enExample)
CA (1) CA2767392C (enExample)
ES (1) ES2573427T3 (enExample)
IL (2) IL217375A (enExample)
MX (1) MX2012000372A (enExample)
WO (1) WO2011005769A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2766521C (en) * 2009-06-25 2020-07-21 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
CA2890084C (en) * 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
JP5650780B2 (ja) * 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN105792843B (zh) * 2013-11-29 2020-02-28 泰尔茂株式会社 佐剂组合物及包含其的疫苗组合物、以及它们的制造方法
WO2016149417A1 (en) * 2015-03-17 2016-09-22 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
AU2016273638B2 (en) * 2015-06-02 2019-06-06 Terumo Kabushiki Kaisha Adjuvant composition containing aluminum and vaccine composition containing the same
GB201612108D0 (en) * 2016-07-12 2016-08-24 Univ Strathclyde Preperation of non-ionic surfactant vesicles and variants
GB201814959D0 (en) * 2018-09-14 2018-10-31 Secr Defence Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses
CN116211827B (zh) * 2023-03-17 2024-04-05 浙江大学 一种特立帕肽固体脂质纳米粒及其制备方法和应用
WO2024226846A2 (en) * 2023-04-26 2024-10-31 Vivtex Corporation Formulation of therapeutic agents for improved permeation

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024241A (en) 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US3952097A (en) 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
JPS56115727A (en) * 1980-02-19 1981-09-11 Kuraray Co Ltd Carrier for immobilizing physiologically active substance
US4537769A (en) 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4894228A (en) 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4983387A (en) 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
DE3867635D1 (de) 1987-03-13 1992-02-20 Micro Vesicular Systems Lipidversikel aus grenzflaechenaktiven stoffen und sterolen.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5160669A (en) 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4911517A (en) 1988-09-09 1990-03-27 Square D Company Means for clamping fiber optical cable
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5817318A (en) 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
CN1022331C (zh) 1989-08-17 1993-10-06 浙江省医学科学院 甲型肝炎减毒活疫苗毒种及其制造方法
DE3934366A1 (de) 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
IT1238343B (it) 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
FI925835L (fi) 1990-06-29 1992-12-22 Chiron Corp Vacciner innehaollande liposomer
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
GB9207731D0 (en) 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
AU4327193A (en) 1992-07-08 1994-01-31 Dianorm-Gerate G. Maierhofer Liposomes, method of preparing them and their use in the preparation of drugs
ES2164074T3 (es) 1992-09-18 2002-02-16 Smithkline Beecham Biolog Vacunas de virus de la hepatitis a.
US5393527A (en) 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
EP0688206B1 (en) 1993-02-26 2000-05-03 Fountain Pharmaceuticals, Inc. Vaccine delivery system and shelf-stable precursor solution for remote encapsulation of active ingredients
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
EP0706374B1 (en) 1993-06-30 1997-12-10 Genentech, Inc. Method for preparing liposomes
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
CN1055093C (zh) 1993-11-17 2000-08-02 实验室奥姆公司 葡糖胺二糖类、其制备方法和用途、以及含有这些二糖的药物组合物
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0733113B1 (en) 1994-01-11 2007-05-02 Vlaams Interuniversitair Instituut voor Biotechnologie Influenza vaccine
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
US20030104576A1 (en) 1994-10-07 2003-06-05 Jonathan W. Nyce Dna construct, composition, formulations & methods for making the construct & for modulating expression
GB9515868D0 (en) 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
GB9522351D0 (en) 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US5700679A (en) 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US6235724B1 (en) 1996-07-03 2001-05-22 Eisai Co., Ltd. Injections containing lipid a analogues and process for the preparation thereof
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
ES2305157T3 (es) * 1996-09-13 2008-11-01 Lipoxen Technologies Limited Liposomas.
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
FR2760367B1 (fr) 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
DE69828507T2 (de) 1997-05-20 2006-01-05 Galenica Pharmaceuticals, Inc. Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
ATE365206T1 (de) 1998-02-13 2007-07-15 Adan Rios Verfahren zur entwicklung von einem hiv impfstoff
US6503753B1 (en) 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
EP1078105B1 (en) 1998-05-12 2004-11-24 Genecure LLC Replication defective hiv vaccine
US7067134B1 (en) 1998-08-12 2006-06-27 University Of Western Ontario HIV vaccine
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9822714D0 (en) 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
CN1062770C (zh) 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
GB9826069D0 (en) 1998-11-28 1999-01-20 Univ Leeds HIV vaccine
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc HIV VACCINE FROM AN ADENOVIRUS CARRYING THE GAG GENE
WO2001005433A2 (en) * 1999-07-14 2001-01-25 Board Of Regents, The University Of Texas System Delivery and retention of activity agents to lymph nodes
AU771706B2 (en) 1999-07-15 2004-04-01 University Of British Columbia, The Methods and apparatus for preparation of lipid vesicles
AU779076B2 (en) 1999-07-28 2005-01-06 Stephen Smith Conditionally controlled, attenuated HIV vaccine
NZ517903A (en) 1999-09-24 2003-10-31 Smithkline Beecham Biolog S One dose intranasal influenza virus vaccine with split influenza viral antigens
WO2001060402A2 (en) 2000-02-15 2001-08-23 Intellivax International Inc. Proteosome influenza vaccine
FR2806912B1 (fr) 2000-04-04 2004-07-23 Fond Mondiale Rech Et Preventi UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US7494659B2 (en) 2000-09-25 2009-02-24 Polymun Scientific Immunbiologische Forschung Gmbh Live attenuated influenza vaccine
ATE374603T1 (de) 2000-12-27 2007-10-15 Ares Trading Sa Amphiphile lipid-nanopartikel zur peptid- und/oder proteininkorporation
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ES2339762T3 (es) 2002-01-14 2010-05-25 Novartis Vaccines And Diagnostics, Inc. Vacuna contra el vih y procedimiento de uso.
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20050169979A1 (en) 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US7604803B2 (en) 2002-07-05 2009-10-20 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination
US20040011840A1 (en) 2002-07-22 2004-01-22 Lovett Terry E. Rolling motorcycle bag
EP1597400B8 (en) 2003-02-25 2013-10-09 MedImmune, LLC Methods of producing influenza vaccine compositions
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
CN1925870A (zh) 2003-05-15 2007-03-07 俄克拉荷马州大学评议会 表达马－2型流感病毒ha1的dna疫苗
AU2004246904B2 (en) 2003-06-18 2010-02-04 Biolab Ltd. Sphingolipids polyalkylamine conjugates for use in transfection
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20050095283A1 (en) 2003-09-16 2005-05-05 Aphios Corporation Compositions and methods for topically treating diseases
US20080160089A1 (en) 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
US7498309B2 (en) * 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
AU2005248361B2 (en) * 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
EP2530147B1 (en) 2004-05-25 2014-09-10 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
DE602005025342D1 (de) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
WO2006002642A2 (en) * 2004-07-07 2006-01-12 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
EP1809246B1 (en) * 2004-10-08 2008-07-16 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
KR101316350B1 (ko) 2004-12-08 2013-10-15 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
EP1676569A1 (en) 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
WO2006092046A1 (en) 2005-03-01 2006-09-08 Variation Biotechnologies Inc. Hiv vaccine composition
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20090028903A1 (en) 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
US7348011B2 (en) 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2006138719A2 (en) 2005-06-17 2006-12-28 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
WO2007120368A2 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
EP1988918A4 (en) 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
US8846078B2 (en) * 2006-03-21 2014-09-30 The Secretary Of State For Environment, Food & Rural Affairs Acting Through The Animal Health And Veterinary Laboratories Agency Brucellosis DNA vaccine
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
JP5072275B2 (ja) * 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
AU2007340343A1 (en) 2006-09-05 2008-07-10 Medivas, Llc Polymer-stabilized liposomal compositions and methods of use
US8273361B2 (en) * 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN101687900A (zh) 2007-03-07 2010-03-31 恩文塔生物制药公司 双链锁核酸组合物
WO2008121926A1 (en) 2007-03-30 2008-10-09 Particle Sciences, Inc. Particle formulations and uses thereof
WO2008153236A1 (en) 2007-06-15 2008-12-18 Protheon Co., Ltd An attenuated influenza virus and a live vaccine comprising the same
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
SI2192917T1 (sl) 2007-08-28 2014-05-30 Baxter International Inc. Postopek za proizvodnjo virusnih cepiv
US20110105995A1 (en) 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
CN101574394A (zh) 2008-05-09 2009-11-11 北京因科瑞斯医药科技有限公司 马钱子生物碱囊泡及其制备方法
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
WO2010033812A1 (en) 2008-09-18 2010-03-25 Variation Biotechnologies, Inc. Compositions and methods for treating hepatitis a.
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012006368A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents

Similar Documents

Publication Publication Date Title
JP2012532200A5 (enExample)
Van Braeckel-Budimir et al. Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications
US20240002127A1 (en) Coronavirus vaccine
CN103096922B (zh) 用于治疗流行性感冒的组合物和方法
MX2012000372A (es) Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
CN107296792B (zh) 囊泡及由其产生之制剂的制备方法
JP2013533259A5 (enExample)
Nguyen et al. Skin immunization with third-generation hepatitis B surface antigen using microneedles
RU2014133089A (ru) Способы и композиции для терапевтических агентов
US11304999B2 (en) Dried composition of saponin in a liposomal formulation with a neutral lipid, a sterol, and a cryoprotectant
CN103501811B (zh) 用于治疗病毒感染的组合物和方法
WO2024209013A1 (en) Lipid nanoparticle compositions
Nielsen et al. ISCOMs as a vaccine delivery system
WO2012006368A2 (en) Compositions and methods for treating influenza
Porte et al. A molecular view of lipid nanoparticles: insights into their morphology and structural plasticity
Kabarkouhi et al. Liposome, nanoliposome and allied technologies in COVID-19 vaccines: key roles and functionalities
JP2018503629A5 (enExample)
EP3016679B1 (en) Method for preparing virosomes
Samiei et al. Engraftment of plasma membrane vesicles into liposomes: A new method for designing of liposome-based vaccines
Khan et al. mRNA vaccines: Immunology and present and future potential
US20200188499A1 (en) Dried composition
Liang et al. A novel method for preparing immune stimulating complexes (ISCOMs) by hydration of freeze-dried lipid matrix
US20160151479A1 (en) Method for preparing virosomes
JP6026339B2 (ja) 経皮吸収剤用のリポソーム担体
KR20160098452A (ko) 바이로좀용의 개선된 제형